Inflectis Bioscience
- Biotech or pharma, therapeutic R&D
InFlectis BioScience is a clinical-stage biotechnology company developing innovative therapies for rare neurological and pulmonary diseases. By targeting multiple disease pathways with multifunctional small molecules, InFlectis aims to deliver disease-modifying treatments for conditions with high unmet medical need. Its lead candidate, IFB-088 (Icerguastat), is a first-in-class, brain-penetrant oral drug currently advancing through preclinical and clinical development.